These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26851154)

  • 1. The potential of computed crystal energy landscapes to aid solid-form development.
    Price SL; Reutzel-Edens SM
    Drug Discov Today; 2016 Jun; 21(6):912-23. PubMed ID: 26851154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can computed crystal energy landscapes help understand pharmaceutical solids?
    Price SL; Braun DE; Reutzel-Edens SM
    Chem Commun (Camb); 2016 Jun; 52(44):7065-77. PubMed ID: 27067116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J; Rohani S
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges.
    Cerreia Vioglio P; Chierotti MR; Gobetto R
    Adv Drug Deliv Rev; 2017 Aug; 117():86-110. PubMed ID: 28687273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cocrystals in pharmaceutical science.
    Shan N; Zaworotko MJ
    Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
    Yin SX; Grosso JA
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-state analysis of the active pharmaceutical ingredient in drug products.
    Newman AW; Byrn SR
    Drug Discov Today; 2003 Oct; 8(19):898-905. PubMed ID: 14554018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Process Analytical Technology for Crystallization of Active Pharmaceutical Ingredients.
    Malwade CR; Qu H
    Curr Pharm Des; 2018; 24(21):2456-2472. PubMed ID: 29956616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques.
    Pindelska E; Sokal A; Kolodziejski W
    Adv Drug Deliv Rev; 2017 Aug; 117():111-146. PubMed ID: 28931472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API.
    Campeta AM; Chekal BP; Abramov YA; Meenan PA; Henson MJ; Shi B; Singer RA; Horspool KR
    J Pharm Sci; 2010 Sep; 99(9):3874-86. PubMed ID: 20575000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction.
    Tona RM; McDonald TAO; Akhavein N; Larkin JD; Lai D
    Lab Chip; 2019 Jun; 19(12):2127-2137. PubMed ID: 31114833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
    Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermal analysis: a further step in characterizing solid forms obtained by screening crystallization of an API.
    Detoisien T; Arnoux M; Taulelle P; Colson D; Klein JP; Veesler S
    Int J Pharm; 2011 Jan; 403(1-2):29-36. PubMed ID: 20951782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid Form Screenings in Pharmaceutical Development: a Perspective on Current Practices.
    Gui Y
    Pharm Res; 2023 Oct; 40(10):2347-2354. PubMed ID: 37537423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Crystallization and solid state properties of molecules of pharmaceutical interest].
    Bauer M
    Ann Pharm Fr; 2002 May; 60(3):152-60. PubMed ID: 12050594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: A review.
    Artusio F; Pisano R
    Int J Pharm; 2018 Aug; 547(1-2):190-208. PubMed ID: 29859921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.